Business
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its clinical stage programs at the upcoming American Academy of Neurology (AAN) 2023 Annual Meeting, held April 22-27, 2023 in Boston, Massachusetts. “Each of our clinical stage programs has made tangible progress in recent months and we look forward to sharing additional details on these programs at the upcoming AAN conference,” said Steven Petrou, Ph.D., co-founder and chief scientific officer of Praxis. “We recently released topline results from the ulixacaltamide Essential1 Phase 2 study in essential tremor and will provide perspective on these data at AAN. Also, we expect to dose the first patients in our PRAX-222 EMBRAVE study and PRAX-562 EMBOLD study within the coming weeks and are excited to share data supporting these programs. Finally, we look forward to sharing new in-vivo results for PRAX-628 that highlight this program’s potential to be a best-in-class treatment for focal epilepsy patients.” Presentation Details: A Novel Approach to Assess the Impact of Disease in Patients with SCN8A-Related Developmental and Epileptic Encephalopathy Session Date/Time: Sunday April 23, 5:30 p.m. – 6:30 p.m. EDTPoster Session P3: 9-008 PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers Session Date/Time: Monday April 24, 8:00 a.m. – 9:00 a.m. EDTPoster Session P4: 9-011 PRAX-628 is a Novel, Well-tolerated, Activity Dependent Sodium Channel Blocker with Potent Anticonvulsant Activity Session Date/Time: Monday April 24, 8:00 a.m. – 9:00 a.m. EDTPoster Session P4: 9-012 PRAX-562-101: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of PRAX-562 in Healthy Volunteers Session Date/Time: Tuesday April 25, 11:45 a.m. – 12:45 p.m. EDTPoster Session P8: 9-011 PRAX-628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care Session Date/Time: Tuesday April 25, 11:45 a.m. – 12:45 p.m. EDTPoster Session P8: 9-012 Disease Impac...